Form 4: Coherus BioSciences Chief Commercial Officer Reports Stock Transaction

Paul Reider, Chief Commercial Officer of Coherus BioSciences, reports the withholding of 2,073 shares for tax obligations related to vesting restricted stock units.

Summary

• Paul Reider, the Chief Commercial Officer of Coherus BioSciences, filed a Form 4 indicating a transaction involving the company's stock.
• On December 13, 2024, 2,073 shares of common stock were withheld to cover tax liabilities associated with the vesting of restricted stock units.
• The price per share for the transaction was $1.61.
• Following the transaction, Reider beneficially owns 89,204 shares of Coherus BioSciences stock.
• This total includes 5,000 shares acquired on November 15, 2024 and 5,000 shares acquired on May 15, 2024 through the company's Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not indicate any positive or negative sentiment. It is a neutral event.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It provides transparency into the stock ownership of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The transaction is typical for executives receiving stock-based compensation, where shares are often withheld to cover tax liabilities.
• Similar filings are made by executives at comparable biotech companies such as Amgen, Gilead, and Biogen.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine tax withholding.
• The filing provides transparency to stakeholders regarding executive stock ownership.

Key Dates

Keywords

Coherus BioSciences, stock transaction, Form 4, insider trading, Paul Reider, Chief Commercial Officer, restricted stock units, tax withholding, employee stock purchase plan